Table 3.
Univariate and Multivariate Predictors of Survival
| Characteristic | HR | 95% CI | P |
|---|---|---|---|
| Univariate | |||
| Fuhrman grade 4 | 1.96 | 1.40–2.74 | <.001 |
| Lung metastasis at diagnosis | 1.79 | 1.36–2.37 | <.001 |
| Liver metastasis at diagnosis | 2.57 | 1.88–3.53 | <.001 |
| Retroperitoneal node involvement at diagnosis | 1.67 | 1.28–2.18 | <.001 |
| Mediastinal node involvement at diagnosis | 1.48 | 1.12–1.94 | .006 |
| Nephrectomy | 0.28 | 0.21–0.37 | <.001 |
| Receipt of TKI | 0.49 | 0.38–0.64 | <.001 |
| MSKCC intermediate-risk disease (1–2) | 2.13 | 1.15–3.94 | .02 |
| MSKCC high-risk disease (31) | 4.03 | 2.14–7.54 | <.001 |
| Multivariate | |||
| Fuhrman grade 4 | 1.78 | 1.27–2.49 | .001 |
| Lung metastasis at diagnosis | 1.91 | 1.30–2.80 | .001 |
| Mediastinal node involvement at diagnosis | 1.60 | 1.12–2.29 | .01 |
| Receipt of TKI | 0.53 | 0.38–0.74 | <.001 |
| ECOG performance score >2 | 1.87 | 1.28–2.71 | .001 |
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MSKCC, Memorial Sloan-Kettering Cancer Center; TKI, tyrosine kinase inhibitor.